22.07.2011 – 21:11

Sartorius AG

EANS-Adhoc: Sartorius AG
Preliminary Figures for the First Half of 2011

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
22.07.2011

Group sales revenue rises 12.2% to EUR353.7 million | Consolidated operating
earnings soar 40.7% to EUR51.1 million; the respective margin improves to 14.4%|
Management raises full-year guidance for sales revenue and profit


In the first half of 2011, order intake for the Sartorius Group grew
13.6%currency-adjusted: +14.6%) from EUR336.4 million to EUR382.3 million. Sales
revenue rose 12.2% (currency-adj.: +13.1%) to EUR353.8 million from EUR315.2
million in the previous year. The Biotechnology Division received orders valued
at EUR257.2 million, up 16.2% (currency-adj.: +17.4%) from EUR221.4 million a
year ago, and increased its sales revenue year on year by 9.7% (currency-adj.:
+10.8%) to EUR229.4 million from EUR209.1 million. For the Mechatronics
Division,order intake climbed 8.7% (currency-adj.: +9.2%) to EUR125.1 million
from EUR115.1 million a year earlier; the division´s revenue grew 17.2%
(currency-adj.: +17.6%) to EUR124.3 million from EUR106.1 million a year ago.

Consolidated underlying EBITA surged from EUR36.3 million to EUR51.1 million;
this reflects earnings before interest, taxes and amortization and is adjusted
for extraordinary items of -EUR6.7 million (prev. yr.: -EUR1.9 mn). The
respective margin jumped from 11.5% to 14.4%. The Biotechnology Division
contributed an underlying EBITA of EUR38.6 million, up from EUR31.5 million a
year ago, which means its margin increased from 15.0% to 16.8%. The Mechatronics
Division more than doubled its contribution to earnings, from EUR4.8 million to
EUR12.4 million; its earnings margin jumped from 4.5% to 10.0%.

Excluding non-cash amortization, underlying net profit after minority interest
for the first half totaled EUR24.0 million (prev. year: EUR15.9 mn); the
respective earnings per share were at EUR1.41, up from EUR0.93 a year ago.

Based on the Group's first-half figures, management has raised its 2011 full-
year guidance for sales revenue and profit, and now projects that sales in
constant currencies will grow for both divisions and thus also for the Group
between 8% and 10% (former guidance: 6% to 8%). The underlying EBITA margin is
forecasted to increase in constant currencies to between 17% and 18% for the
Biotechnology Division (former guidance: about 17%) and to between 10% and 11%
for the Mechatronics Division (former guidance: about 8%). Accordingly, the
operating EBITA margin at Group level is expected to improve to between 14.5%
and 15.5% (former guidance: about 14%). Moreover, management continues to
anticipate that in 2011 operating cash flow will be significantly positive.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will
discuss the results with analysts and investors on Monday, July 25, 2011, at
4:00 p.m. Central European Time in a webcast teleconference.
You may dial into the teleconference starting at 3:45 p.m. CET at the following
numbers: Germany +49 (0)69 2222 2244; France +33(0)1 70 99 42 73; UK +44(0)20
7136 2052; USA +1 212 444 0481. The dial-in code is as follows: 9817884

The webcast and presentation can be viewed at www.sartorius.com.


Goettingen, July 22, 2011



-----------------------
Sartorius AG
37070 Goettingen, Germany

Andreas Wiederhold

Phone +49(0)551.308.1668
Fax +49(0)551.308.3153
andreas.wiederhold@
sartorius.com
www.sartorius.com


|Ad hoc Announcement                |[pic]                                     |


Further inquiry note:
Henriette Meyer
Treasury & Investor Relations
Tel.: +49 (0)551-308-3232
E-Mail:  henriette.meyer@sartorius.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      Sartorius AG
             Weender Landstr. 94-108
             D-37075 Göttingen
phone:       +49 (0)551 308-0
FAX:         +49 (0)551 308-3289
mail:         info.investor@sartorius.com
WWW:         http://www.sartorius.com
sector:      Biotechnology
ISIN:        DE0007165607, DE0007165631
indexes:     CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, Hannover, München 
language:   English